Abstract
AbstractBestrophinopathies are a group of clinically distinct diseases caused by mutations in Bestrophin1 (BEST1). BEST1 is expressed exclusively in the retinal pigment epithelial (RPE) cells of the eye, where it functions as an ion channel. Mutations in the BEST1 gene affect the function of the RPE leading to the death of overlying retinal cells and subsequent vision loss.The dominant and recessive nature of Bestrophinopathies may necessitate different approaches to prevent or ameliorate these diseases. Potential therapeutic options for Bestrophinopathies focus on restoring correct gene expression, though viral gene therapy and gene editing, or by targeting nonsense mutations through translational readthrough‐inducing drugs. We are using induced pluripotent stem‐derived RPE created from patients with Bestrophinopathies to investigate these potential therapies in vitro.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
